Evidence For Pd 1 Pd L1 Combination Immunotherapie

The role of combining immunotherapy with primary (Chemo)radiotherapy in curative treatment settings of the head and neck

Combination with Stereotactic Body Radiotherapy Offers a Promising Strategy to Overcome Resistance to Immunotherapy in A

Translating Knowledge About the Immune Microenvironment of Gastrointestinal Stromal Tumors into Effective Clinical Strat

Abscopal Effects and Immunomodulation in Skin Cancer Therapy.

Combining conventional therapy with immunotherapy: A risky business?

Personalized cancer vaccines and their integration with standard of care modalities.

Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?

Experimental Investigation of Hematological Toxicity After Radiation Therapy Combined With Immune Checkpoint Inhibitors.

Combining immunotherapies for the treatment of prostate cancer.

Time to abandon single-site irradiation for inducing abscopal effects.

Lung Cancer: Advances in Diagnosis and Management

Lighting up the fire in cold tumors to improve cancer immunotherapy by blocking the activity of the autophagy-related pr

Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy.

Targeted Therapies Combined With Immune Checkpoint Therapy.

Clinical outcomes and longitudinal circulating tumor DNA changes after treatment with nivolumab and olaparib in immunoth

Low-dose irradiation for reversing immunotherapy resistance: how to translate?

Radiotherapy for Melanoma: More than DNA Damage.

Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies.

Oligometastatic Melanoma Treated by Metastasectomy in Combination with Immune Checkpoint and BRAF Inhibitors: A Case Ser

Synergies of Targeting Angiogenesis and Immune Checkpoints in Cancer: From Mechanism to Clinical Applications.

Combination approaches in NSCLC involving immune checkpoint inhibitors.

Prospects for Treatment of Lung Cancer Using Activated Lymphocytes Combined with Other Anti-Cancer Modalities

Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies.

Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients.

Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy.

Modulation of CD8+ T Cell Responses by Radiotherapy-Current Evidence and Rationale for Combination with Immune Checkpoin

Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Ev

HOOK1 Inhibits the Progression of Renal Cell Carcinoma via TGF‐<i>β</i> and TNFSF13B/VEGF‐A Axis

Systemic treatments for metastatic cutaneous melanoma

First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an I

Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment

Lung cancer: current therapies and new targeted treatments

Advancing immunotherapy for early-stage triple-negative breast cancer

Regulatory T cells in cancer immunotherapy

Head and neck squamous cell carcinoma

Immunotherapy in colorectal cancer: rationale, challenges and potential

Advances in immunotherapy for hepatocellular carcinoma

A guide to cancer immunotherapy: from T cell basic science to clinical practice

Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment

Novel immunotherapy combinations for genitourinary cancers

Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns

Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with

First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melano

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Regulation of programmed death‐ligand 1 expression in response to DNA damage in cancer cells: Implications for precision

Dahuang Fuzi Baijiang decoction restricts progenitor to terminally exhausted T cell differentiation in colorectal cancer

Side effect management during immune checkpoint blockade using CTLA‐4 and PD‐1 antibodies for metastatic melanoma – an u

Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance

Genomic Profiling of Radiation-Induced Sarcomas Reveals the Immunologic Characteristics and Its Response to Immune Check

Combination Therapies to Improve the Efficacy of Immunotherapy in Triple-negative Breast Cancer

PD-1 Checkpoint Inhibitor Associated Autoimmune Encephalitis

Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia

Combinatorial approach to cancer immunotherapy: strength in numbers

Plinabulin, a novel small molecule clinical stage IO agent with anti-cancer activity, to prevent chemo-induced neutropen

Phase II study of ipilimumab, nivolumab, and panitumumab in patients with <i>KRAS</i>/<i>NRAS</i>/<i>BRAF</i> wild-type

Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin&#x27;s Lymphom

Non-small cell lung cancer: current treatment and future advances

Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy

Immunotherapy Combinations for the Treatment of Patients with Solid Tumors

MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer

Programmed cell death protein-1 inhibitor for the treatment of hepatocellular carcinoma: “A sharp sword”

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021

Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology